HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TCPI Plans Strategic Alliance For Private Label Nicotine Patch

This article was originally published in The Tan Sheet

Executive Summary

Technical Chemicals & Products, Inc. plans to develop a "strategic alliance" for its private label nicotine patch. The firm's development of an ANDA for a nicotine patch equivalent to SmithKline Beecham's NicoDerm CQ system is under way, although it has not yet filed an ANDA. Waxman/Hatch marketing exclusivity for SB's nicotine patch expires Aug. 2.

You may also be interested in...

Novartis OTC Habitrol Taking Private Label Tack

Novartis Consumer Health is planning a "major" private label initiative with its newly approved OTC nicotine patches involving Wal-Mart, CVS and Walgreens. The firm intends to later market the product under its original Habitrol name, but the initial focus is in the private label setting. OTC Habitrol was approved Nov. 12.

Watson Private Label Nicotine Gum Launching In September

Watson Pharmaceuticals will introduce its private label nicotine polacrilex gum "before the end of the third quarter," the company announced during a conference call with securities analysts Aug. 5. Retail chains that have agreed to carry the product include CVS, Walgreen, Rite-Aid, Eckerd, American Stores and Wal-Mart.

SmithKline Nicorette Mint Spurs Gum Sales 8% In Second Quarter

SmithKline Beecham total smoking cessation sales increased 11% to $122 mil. in the second quarter, the firm reported July 20. The gain represents a slowdown, however, from first quarter growth of 68%.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts